The widely used analgesic-antipyretic drug acetaminophen (APAP) is known to cause serious liver necrosis at high doses in man and experimental animals. For studies of toxic processes, 1H NMR spectroscopy of biofluids allows monitoring of endogenous metabolite profiles that alter characteristically in response to changes in physiological status. Herein, a 1H NMR metabolomics approach was applied to the investigation of APAP toxicity in rats and the effect of phenobarbital (PB) on APAP-induced hepatotoxicity. Metabolite differences due to hepatotoxicity were observed in 1H NMR spectra of serum and urine, and enhanced APAP hepatotoxicity by pretreatment with PB was clearly shown by a principal components analysis of the spectral data. NMR spectra of APAP-dosed rat urine provided profiles of APAP-related compounds together with endogenous metabolites. By comparison of endogenous and APAP-related metabolite spectra with those from rats pretreated with PB, it was possible to show the importance of oxidative metabolism of APAP to N-acetyl-p-benzoquinone, an essential step in APAP hepatotoxicity.
Introduction
Acetaminophen ¤APAP¥ is a widely used analgesic and antipyretic drug that is generally safe and nontoxic when administered at therapeutic doses.
1,2¥ However, when administrated in large doses, it can cause acute hepatic centrilobular necrosis in both humans and experimental animals. APAP is mainly detoxified in the liver by glucuronidation or sulfo-conjugation. 3¥ Depending on the dose, a fraction of APAP can also be metabolized by microsomal cytochrome P450-dependent oxidation to Nacetyl-p-benzoquinone ¤NAPQI¥, a highly reactive and toxic intermediate. 4,5¥ At low doses, NAPQI is trapped by conjugation with intracellular glutathione ¤GSH¥ to form a glutathione metabolite. 2¥ The glutathione conjugate can be further metabolized to a cysteine derivative and mercapturate in the kidneys and liver, and the mercapturate is then excreted into urine.
6,7¥ At high doses of APAP, however, GSH is rapidly depleted, and the accumulated NAPQI binds to cellular proteins causing cell injury and death.
8®10¥
Phenobarbital ¤PB¥ is a well-known enzyme inducer that induces many isozymes of the cytochrome P450 family.
Acute potentiation of APAP toxicity by PB has been reported to occur in mice and has been associated with the direct inhibition of UDP-glucuronosyltransferase by PB or depletion of hepatic UDP-glucuronic acid due to the formation of a PB glucuronide. 11¥ Interestingly, pretreatment of rats with PB prior to APAP administration increases urinary excretion and impairs biliary excretion of APAP glucuronide.
12,13¥
Recently, analytical techniques such as mass spectrometry ¤MS¥, nuclear magnetic resonance ¤NMR¥, and gas chromatography/mass spectrometry ¤GC/MS¥ coupled with multivariate analysis have been employed to evaluate drug toxicity and the progress of disease or toxic response. Among these, NMR can give much more structural information than other analytical techniques, and the technique is favorable for obtaining an enormous amount of information about the molecular structure of biochemicals, endogenous compounds, and drug metabolites from one-and two-dimensional NMR spectra. In the study of toxic processes and metabolic diseases, 1H NMR spectroscopy of biofluids allows the monitoring of endogenous metabolite profiles that are characteristically altered in response to changes in physiological status, toxic insult, or disease processes.
14,15¥ By the application of simultaneous multivariate statistical analyses, it is possible to explore relationships between metabolite composition and toxicity and to generate novel combination biomarkers for toxicity. 1H NMR-based metabolomic studies that systematically explore the relationships between metabolite composition and toxicity can be used to define biomarkers characterizing APAP-induced liver damage. At high doses of APAP, the major biochemical changes in liver tissue are an increase in lipid triglycerides and monounsaturated fatty acids together with a decrease in polyunsaturated fatty acids. 16¥ These changes are attributable to mitochondrial malfunction and are consistent with the observed enhanced levels of glucose and lactate in plasma.
In metabolomic investigations into APAP toxicity, APAPrelated metabolites, including APAP itself, together with the signals of endogenous metabolites are found in 1H NMR spectra of urine from rats administered APAP, 17¥ and in general, multicomponent analyses of the urine spectra are performed by binning the spectral data excluding the regions of APAP-related metabolites. 16¥ However, determining the amounts and relative proportions of APAP-related metabolites excreted by rats may be useful for ascertaining the metabolites and metabolic pathways that play an important role in the development of APAP-induced toxicity. Herein, we describe results of a study focused on the composition of 1H NMR-detectable APAP-related metabolites in rat urine along with endogenous metabolites in both urine and serum, and through enhanced toxicity induced by pretreatment of rats with PB, the implication of the metabolic conversion of APAP to the toxic metabolite NAPQI is evaluated.
Materials and Methods
Chemicals: Acetaminophen and deuterium oxide ¤D 2 O, isotopic purity 99.9%¥ containing 0.75% 3-¤trimeth-ylsilyl¥propionic-2,2,3,3-d 4 acid, sodium salt ¤TSP¥ were purchased from Sigma-Aldrich ¤St. Louis, MO¥. TSP was used as an internal standard with a chemical shift ¤É¥ of 0.0 ppm for 1 H NMR measurements. All other reagents, including phenobarbital, were purchased from Wako Pure Chemicals ¤Tokyo, Japan¥.
Animal studies: All animal studies were conducted in accordance with the guidelines of the Institutional Animal Care and Use Committee of Daiichi Sankyo Co., Ltd. Male F344/DuCrlCrlj rats ¤8 weeks old¥ were purchased from Charles River Laboratories Japan, Inc. ¤Kanagawa, Japan¥. All animals were maintained under standard conditions with a 12-h light/dark cycle and were treated humanely. Food and water were available ad libitum. Animals were allowed to acclimate for a week prior to dosing. After being dosed with PB at 0 or 100 mg/kg for 4 days, rats ¤n © 5¥ were administered 0, 500, or 800 mg/kg of APAP; the rats were placed in metabolism cages for urine collection for a period of 24 h. All treatments were administered via oral gavage, and urine samples were stored at %80ôC until analyzed by NMR spectroscopy. Blood was collected under ether anesthesia from the abdominal aorta of each animal using a disposable syringe 24 h after dosing with APAP, and the collected blood samples were placed in separating agentcontaining conical centrifuge tubes. Thereafter, the samples were allowed to stand at room temperature for about 30 min and centrifuged at 3000 rpm and 4ôC for 10 min with a refrigerated centrifuge. The serum samples for clinical pathology or NMR measurement were stored in a freezer ¤set temperature %80ôC¥ until use.
Clinical pathology: Standard spectrometric methods on a TBA-2000FR analyzer ¤Toshiba Medical Systems¥ were used for the measurement of the following serum parameters: aspartate aminotransferase ¤AST¥, alanine aminotransferase ¤ALT¥, alkaline phosphatase ¤ALP¥, and bilirubin.
1H NMR spectroscopic analysis of blood serum: A total of 534 µL of blood serum was dissolved in 60 µL of 5 mM TSP/D 2 O and 6 µL of 1 M imidazole/D 2 O to produce a 600 µL solution for NMR measurements. TSP and imidazole were taken as a qualitative standard for the chemical shift scale and the pH indicator for serum, respectively. The samples were placed in 5-mm NMR tubes, and 1H NMR spectra were recorded at 298 K using a Varian 600-MHz NMR spectrometer equipped with a cold probe. One-dimensional single pulse experiments were carried out using the NOESY pulse sequence to achieve satisfactory water suppression. For each sample, 32 transients were collected into 77 K data points using a water presaturation pulse sequence ¤D-90ô-t 1 -90ô-t m -90ô-acquire FID¥. A secondary irradiation field was applied at the water frequency during the relaxation delay of 2 s and the mixing period t m ¤100 ms¥, with t 1 fixed at 3 µs. A spectral width of 8445.9 Hz and an acquisition time per scan of 4.00 s were used. The one-dimensional Carr-Purcell-Meiboom-Gill ¤CPMG¥ spin-echo pulse sequence ª90ô-¤r-180ô-r¥ n acquisition« ¤r © 153.3 ms, n © 114¥ with one-dimensional 1H NOESY presaturation of the water resonance, using a fixed total spin relaxation delay ¤T 2 ¥ of 50 ms was applied to measure spin-echo 1H NMR spectra for all samples. After Fourier transformation with 0.3-Hz line broadening and a single zero-filling, 1H spectra were phased and baseline corrected, and the chemical shift scale was set by assigning a value of É © 0 ppm to the signal for the internal standard TSP. Metabolite identification was accomplished using the NMR Suite ver. 6.0 software ¤Chenomx Inc., Calgary, Canada¥. Literature data were used to confirm the metabolite identification.
1H NMR spectroscopic analysis of urine: Urine samples for NMR spectroscopy were centrifuged at 3000 rpm for 5 min, and the supernatants ¤534 µL¥ were dissolved in 60 µL of 5 mM TSP/D 2 O and 6 µL of 1 M imidazole/D 2 O to produce a 600 µL solution for NMR measurements. TSP and imidazole were taken as a qualitative standard for the chemical shift scale and the pH indicator for urine, respectively. The samples were placed in 5-mm NMR tubes, and 1H NMR spectra were recorded at 298 K using a Varian 600 MHz NMR spectrometer equipped with a cold probe. The water resonance was suppressed by presaturation during the first increment of the NOESY pulse sequence, with irradiation occurring during the 2.0-s relaxation delay and also during the 100-ms mixing time. Thirty-two free induction decays ¤FIDs¥ with 77 kbyte data points per FID were collected using a spectral width of 9615.4 Hz, an acquisition time of 4.00 s, and a total pulse recycle delay of 2.02 s. After Fourier transformation with 0.3-Hz line broadening and a single zero-filling, 1H spectra were phased and baseline corrected, and the chemical shift scale was set by assigning a value of É © 0 ppm to the signal for the internal standard TSP. Endogenous metabolites in the spectra were assigned using the NMR Suite 6.0 software. The assignment of APAP-related metabolites was made on the basis of literature data. 17¥ Correlation between the resonances of the endogenous metabolites and APAP-related metabolites was further confirmed by two-dimensional TOCSY.
NMR data reduction and principal components analysis ¤PCA¥: For PCA, all 1H NMR spectra were phased and baseline corrected by the NMR Suite 6.0 software, professional edition ¤Chenomx¥. Each 1H NMR spectrum was then subdivided into regions having an equal bin size of 0.03 ppm over a chemical shift range of 0.5® 9.0 ppm, and the regions within each bin were integrated. The region of the spectrum that included water ¤É 4.6®5.0¥ was removed from the analysis for all groups to eliminate variation in water suppression efficiency. For urine spectra, the regions containing urea and APAP-related metabolites ¤É 2.10®2.20, É 3.75®3.85, É 5.05®5.15, É 5.50®5.85, É 6.75®7.45¥ were also removed. The integrated intensities were then normalized to the total spectral area, and the data was converted from the NMR Suite software format into Microsoft Excel format ¤*.xls¥. The resultant data sets were then imported into SIMCA-P version 12.0 ¤Umetrics AB, Umeå, Sweden¥ for multivariate statistical analysis, and PCA was performed to examine the intrinsic variation in the data set. Score plots of the principal components ¤PCs¥ were constructed to visualize any inherent separation of dose groups, and from the values of the PC loadings, NMR spectral regions and hence biomarkers were identified. The levels of APAP-related metabolites were determined on the basis of the concentration of tyrosine relative to its peak intensity by using the 600-MHz library from the NMR Suite 6.0.
Results
Clinical chemistry: Shown in Table 1 are the serum clinical chemistry measurements in rats following APAP dosing with or without PB pretreatment. A single oral administration of 500 mg/kg of APAP did not affect the level of serum aspartate aminotransferase activities ¤AST and ALT¥, whereas pretreatment with PB increased the level of serum AST and ALT activity, indicating a toxicological effect of APAP on the liver. In contrast, administration of 800 mg/kg of APAP-induced liver toxicity both with and without PB treatment, consistent with significantly increased levels of AST and ALT.
Metabolomic analysis of rat serum: Representative spectra of blood serum samples from rats treated with 0, 500, or 800 mg/kg of APAP 24 h postdose are given in Figure 1 . These spectra show resonances from low molecular weight metabolites with contributions from higher molecular weight peaks such as lipoproteins, partially attenuated through spin-echo spectral editing. The endogenous metabolites in the spectra were assigned on the basis of literature values. Compared with control rats, administration of 500 mg/kg of APAP influenced to a lesser extent the resonance profiles of both macromolecules and low molecular weight metabolites except for an increase in resonances corresponding to creatinine. The dominant visible biochemical changes were observed for rats treated with 800 mg/kg of APAP, which showed an increase in isoleucine and pyruvate, and significant increases in lactate, TMA, and creatinine. A reduction in lipid level was also indicated by the broad macromolecular resonance profile in the regions of the spectra between 2.7®2.8, 1.25®1.3, and 0.85®0.90 ppm. The resonances for APAP and related metabolites such as glucuronide or sulfate were not detectable in serum 1H NMR spectra due to rapid clearance of these metabolites. Shown in Figure 2 are mean score plots for the first two PCs of the data-reduced 1H NMR spectra of whole serum following dosing with APAP. It was apparent that an effect of APAP could be observed in the upto-down shift on PC2, while only a partial separation of the 500 mg/kg group from the control was observed. From comparison of the loading plots of PC1 and PC2 ¤data not shown¥, this separation of PC2 between control and APAP- 1H NMR-based Metabolomics of Acetaminophendosed samples is primarily attributable to endogenous metabolites, such as lactate, creatinine, and TMA, which are identical to those corresponding to the visible biochemical changes in Figure 1 . Although serum spectra of PB-pretreated and untreated rats were clearly separated in PC1, the endogenous metabolites characteristic of PB pretreatment could not be identified by the loading plots. Metabolomic analysis of rat urine: Six-hundredmegahertz 1H NMR spectra of typical urine samples obtained 0®24 h postdose from rats dosed with APAP at 0, 500, or 800 mg/kg are shown in Figure 3 . In comparison to control rats, the major biochemical changes identified in rat urine following treatment with 500 or 800 mg/kg of APAP were a decrease in the intensity of resonances for allantoin, hippurate, creatinine, trimethylamine N-oxide ¤TMAO¥, and tricarboxylic acid ¤TCA¥ cycle intermediates such as 2-oxoglutarate, citrate, and succinate. Conversely, the intensity of resonances for taurine and Fig. 1 . Six-hundred-megahertz 1H NMR spectra of serum from rats dosed with APAP at (A) 0 mg/kg, (B) 500 mg/kg, and (C) 800 mg/kg Endogenous metabolites were assigned based on literature sources as indicated. TMA, trimethylamine; VLDL, very low density lipoprotein; LDL, low-density lipoprotein. Fig. 2 . Score plots of PC1 and PC2 of the mean data from 1H NMR-based metabolomic analysis of serum data Symbols denote individual serum samples from rats dosed with 0 (circles), 500 (triangles), and 800 (diamonds) mg/kg of APAP with (closed symbols) or without (open symbols) PB pretreatment. The region of the spectra including water was removed from the PC analysis for all groups. Fig. 3 . Six-hundred-megahertz 1H NMR spectra of urine from rats dosed with APAP at (A) 0 mg/kg, (B) 500 mg/kg, and (C) 800 mg/kg Endogenous metabolites were assigned from literature sources as indicated. TMAO, trimethylamine N-oxide; DMG, dimethylglycine.
lactate increased in these urine samples following APAP dosing. Among 1H NMR-detectable TCA intermediates, the 2-oxoglutarate resonances decreased prior to loss of citrate and succinate resonances, suggesting that reduced levels of 2-oxoglutarate were due to metabolic routes other than the TCA cycle. A similar change of 2-oxoglutarate in urine metabolites has been reported for the toxic effects of hydrazine, a model hepatotoxin. In the dose dependence of APAP toxicity, an increase of lactate and a decrease of TMAO in urine were also noted, which were characteristic of rats dosed with 800 mg/kg of APAP as compared with the 500 mg/kg dose.
The dose dependence of APAP toxicity and the effects of PB on APAP toxicity were investigated by applying PCA to the data set of 1H NMR urine spectra from controls and all the available tested animals. Because the spectra obtained from the urine of rats dosed with APAP gave rise to APAP metabolite signals along with endogenous metabolites, PC maps were generated from the spectra from which the regions containing APAP and its metabolites were removed. The score plot of PC1 versus PC2 for the NMR data from rat urine following dosing with APAP is shown in Figure 4 . The score plot in PC1 revealed a clear separation between the control and APAP-dosed animals both with and without PB pretreatment, and the 800 mg/kg group was further separated from the control group than the 500 mg/kg group was, indicating a biochemical alteration in response to the toxicological effects of APAP. The metabolites responsible for the separation seen in the score plot were identified from the loading plots, i.e., the spectral regions shown to the right of the loading plot consist of allantoin, hippurate, and TCA intermediates, which were decreased in the APAP-dosed rats. Consequently, it was apparent that the dose dependence of the APAP toxicological effect could be observed by the shift on PC1 in the score plot, and the metabolites responsible for the dose-dependent shift on PC1 are in agreement with the visible alterations seen in the spectra. In addition, there was a clear separation between the rat groups with and without pretreatment of PB in PC2. The corresponding loading plot ¤not shown¥ revealed that the separation seen in PC2 of the score plot was the result of a large increase in the resonance intensity of taurine in rats pretreated with PB. There was also separation in PC1 between untreated control rats and rats pretreated with PB; therefore, with PB treatment, APAP-dosing groups were further separated from the control group in PC1 compared with the separation responsible for the effect of APAP in the PB untreated groups. This suggests that the toxicologically significant effect of APAP increased in the PB pretreatment group of rats by the enhanced biochemical alterations expected from further separation in PC1 of the score plot.
APAP-related metabolites: The NMR spectra of urine from APAP-dosed rats provided profiles of APAPrelated compounds and unmetabolized APAP superimposed on endogenous metabolites. Figure 5 depicts a typical aromatic region of the NMR spectra. It was possible to observe 1H NMR peaks from the major metabolites of APAP, namely, the sulfate, glucuronide, and N-acetylcysteine conjugates along with unmetabolized APAP, the structures of which were assigned on the basis of literature values and were further confirmed by two-dimensional TOCSY. It was apparent that these APAP-related metabolites excreted in urine differ in ratio depending on the dose of APAP. Therefore, the major metabolites observed in urine were quantified and compared among various treatment groups as shown in Figure 6 . In urine from rats dosed with 500 mg/kg of APAP without PB pretreatment, the sulfate conjugate was the primary APAP metabolite, followed by glucuronide, APAP, and mercapturate. Interestingly, the level of sulfate conjugate from APAP dosing at 800 mg/kg was decreased compared to dosing at 500 mg/kg, whereas the level of glucuronide conjugate for 800 mg/kg of APAP was significantly increased compared to dosing at 500 mg/kg. The levels of mercapturate were similar in the 500 and 800 mg/kg APAP dose groups, suggesting that saturation of glutathione metabolism occurs at these dosing levels, leading to accumulation of the toxic NAPQI metabolite. The level of unmetabolized APAP for 800 mg/kg of APAP dosing significantly increased about 4-fold over that of 500 mg/kg, indicating that the cytochrome P450 system is insufficient for biotransformation at the 800 mg/kg dosing level. Compared with APAP dosing alone, pretreatment with PB did not significantly elevate levels of sulfate, glucuronide, or mercapturate for both 500 and 800 mg/kg APAP-dosed rats. Importantly, PB treatment dramatically decreased the urinary level of unmetabolized APAP in rats dosed with APAP not only at 500 mg/kg but also at 800 mg/kg. This suggests that the enhanced activity of cytochrome P450 due to PB makes it possible to metabolize APAP to NAPQI and results in lower levels of APAP excreted in urine. The region of the spectra including water, urea, and metabolites of APAP was removed from the PC analysis for all groups.
1H NMR-based Metabolomics of Acetaminophen
Discussion APAP is metabolized primarily through glucuronidation and sulfation pathways and then is excreted in urine. Although only a small amount of APAP undergoes oxidative metabolism with cytochrome P450 ¤CYP¥ to form the reactive metabolite NAPQI followed by enzymatic or nonenzymatic conjugation with GSH, this route plays an important role in the toxicity induced by APAP. In this report, a NMR metabolomics approach was applied to the . Analysis of APAP and APAP metabolites in urine samples of rats dosed with 500 or 800 mg/kg of APAP without or with pretreatment with 100 mg/kg of PB The p value was ascertained using Student's t test, and differences were considered significant for p g 0.05 (*), 0.01 (**), or 0.001 (***).
investigation of APAP toxicity in rats as well as to clinical chemistry measurements, and the effect of PB, an effective inducer of CYP, on hepatotoxicity was examined in order to determine the importance of NAPQI.
Clinical chemistry measurements from a 500 mg/kg dose of APAP alone after 24 h revealed that the levels of ALT and AST were similar to those in control rats. Metabolic recovery from the effect of 500 mg/kg of APAP proceeded in 24 h and resulted in low levels of ALT and AST, whereas hepatotoxic effects remained in rats pretreated with PB or dosed with 800 mg/kg of APAP, which suggests an enhancement of the toxicological response to APAP administration induced by PB.
APAP produces a wide range of metabolic perturbations across several organs and tissues. At a dose of 500 mg/kg, a decrease in the intensities of resonances from hippurate, citrate, succinate, and 2-oxoglutarate were observed in urine 1H NMR spectra. Conversely, the intensity of resonances from taurine was increased. In rat serum, administration of 800 mg/kg APAP resulted in an increase in lactate, TMA and creatinine and a decrease in lipid level. These biochemical changes in both urine and serum are in agreement with the results of Coen et al., indicating the characteristics of APAP-induced hepatotoxicity 18¥ as well as the increase of clinical biomarkers such as ALT or AST. Such biochemical alterations due to hepatotoxicity induced by APAP were also observed to significantly increase with PB pretreatment, which suggests the involvement of CYP oxidative metabolism in the development of toxicity. The PB-mediated increase in APAP toxicity is responsible for the higher levels of NAPQI, the formation of which proceeds via oxidation by CYP. In rats, the oxidation of APAP is catalyzed by the constitutive forms CYP1A2, 2E1, and 3A2 and the inducible forms CYP3A1 and 1A1, 19¥ while in humans it is catalyzed by CYP2E1, 1A2, and 3A4.
20¥
Shown in Figure 7 is a possible biotransformation pathway of APAP. NAPQI formed from APAP by CYP is conjugated either enzymatically or nonenzymatically with GSH. The GSH conjugate can then be further metabolized in the liver and kidneys to form mercapturic acid, which could be observed in NMR spectra. The glucuronide and sulfate of APAP and unmetabolized APAP were also observed in urine. Compared with the levels of APAP metabolites from APAP doses of 500 mg/kg, treatment at 800 mg/kg led to an increase in the level of glucuronide and APAP. In contrast, only a slight increase in the level of mercapturate was found, which suggests that the detoxifying capacity of the liver becomes saturated with the depletion of GSH, and therefore the toxic NAPQI metabolite accumulates. Interestingly, the level of unmetabolized APAP significantly decreased on PB pretreatment, while the level of APAP metabolites was unaffected. A decreased level of APAP is thought to result from enhanced oxidative metabolism of APAP to the cytotoxic metabolite NAPQI induced by PB. 1H NMR-based Metabolomics of AcetaminophenNAPQI is known to be both an oxidizing and an arylating agent. 21¥ At toxic doses of APAP, glutathione is depleted and the higher level of NAPQI metabolite produces the observed toxicity by oxidation of thiol groups in mitochondria, leading to mitochondrial permeability transition. 22¥ Thus, toxicity is mediated by mitochondrial dysfunction resulting in production of reactive oxygen species. It has been reported that the perturbation of metabolic pathways related to APAPinduced hepatotoxicity is characterized by an increase in ophthalmic acid, an oxidative stress biomarker. 23¥ An apparent dose-dependent decrease in TCA metabolites observed in this study strongly supports the contribution of mitochondrial dysfunction caused by NAPQI during the development of APAP-induced hepatotoxicity.
Finally, pretreatment of rats with multiple doses of PB potentiates APAP hepatotoxicity through induction of cytochrome P450, thus increasing the formation of NAPQI, a reactive APAP metabolite. The 1H NMR spectra of urine and serum of APAP-treated rats exhibited differences in biochemical data due to hepatotoxicity together with APAPrelated metabolites. By comparison of endogenous and APAP-related metabolites from control and PB pretreated rats, it was possible to show the essential importance of NAPQI for APAP-induced hepatotoxicity via an enhanced oxidative metabolism mechanism. Taken together, this 1H NMR metabolomics approach using biofluid spectra may lead to effective methods for monitoring drug-related metabolites while also allowing the identification of novel biomarkers of hepatotoxicity.
